Sodium-glucose cotransporter type 2 inhibitors and heart failure with preserved ejection fraction: the EMPEROR-Preserved and DELIVER studies

被引：0
|
作者：
Tomasoni, Daniela
Stretti, Lorenzo
Adamo, Marianna
Metra, Marco
机构：
[1] Univ Brescia, Dipartimento Cardiotorac, UO Cardiol, ASST Spedali Civili Brescia, Brescia, Italy
[2] Univ Brescia, Dipartimento Specialita Med Chirurg Sci Radiol &, Brescia, Italy
来源：
GIORNALE ITALIANO DI CARDIOLOGIA | 2023年 / 24卷 / 04期
关键词：
CARDIOVASCULAR OUTCOMES; EMPAGLIFLOZIN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：251 / 254
页数：4
相关论文
共 50 条
  • [31] Prescribing Trends of Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Heart Failure with Preserved, Mildly Reduced and Reduced Ejection Fraction
    Hofer, F.
    Hammer, A.
    Steinacher, E.
    Baumer, U.
    Kazem, N.
    Koller, L.
    Richter, B.
    Hengstenberg, C.
    Sulzgruber, P.
    Niessner, A.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S475 - S475
  • [32] Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
    Fukuta, Hidekatsu
    Hagiwara, Hiromi
    Kamiya, Takeshi
    IJC HEART & VASCULATURE, 2022, 42
  • [33] Sodium-glucose co-transporter 2 inhibitors: drugs with multiple effects, but which one is relevant to heart failure with preserved ejection fraction? Letter regarding the article 'Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR-Preserved trial'
    Kokhan, Elizaveta
    Kiyakbaev, Gayrat
    Medovchshikov, Vadim
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (07) : 1323 - 1324
  • [34] Time-Varying Cardiovascular Effects of Sodium-Glucose Cotransporter Inhibitors in Patients With Heart Failure With Preserved Ejection Fraction
    Zahid, Salman
    Khan, Safi U.
    AMERICAN JOURNAL OF CARDIOLOGY, 2023, 201 : 390 - 391
  • [35] A Review of Sodium-Glucose Cotransporter 2 Inhibitor's Clinical Efficacy in Heart Failure With Preserved Ejection Fraction
    Epperson, Jacob
    Athar, Zoraize Moeez
    Arshad, Mahnoor
    Chen, Edward
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (04)
  • [36] EMPEROR-Preserved: Empagliflozin and Outcomes in Heart Failure with a Preserved Ejection Fraction and Chronic Kidney Disease
    Wanner, Christoph
    INTERNIST, 2022, 63 (SUPPL 3): : 349 - 349
  • [37] Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved
    Coats, Andrew J. S.
    Butler, Javed
    Tsutsui, Hiroyuki
    Doehner, Wolfram
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Boehm, Michael
    Chopra, Vijay K.
    Verma, Subodh
    Nordaby, Matias
    Iwata, Tomoko
    Nitta, Daisuke
    Ponikowski, Piotr
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2024, 15 (01) : 412 - 424
  • [38] Uric Acid and Treatment With Empagliflozin in Heart Failure With Preserved Ejection Fraction: The EMPEROR-Preserved Trial
    Doehner, Wolfram
    CIRCULATION, 2022, 146
  • [39] Eligibility of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction: Insights from the Colombian heart failure registry (RECOLFACA)
    Gomez-Mesa, Juan Esteban
    Saldarriaga, Clara
    Rivera-Toquica, Alex Arnulfo
    Arrieta-Gonzalez, Silfredo
    Munoz-Velasquez, Alfonso
    Echeverry-Navarretei, Eduardo Jose
    Lugo-Pena, Julian Rodrigo
    Ceron, Juan Alberto
    Rincon-Pena, Oscar Sveins
    Silva-Diazgranados, Luis Eduardo
    Osorio-Carmona, Hugo Ernesto
    Posada-Bastidas, Alejandro
    Garcia, Juan Camilo
    Ochoa-Moron, Alejandro David
    Echeverria, Luis Eduardo
    IJC HEART & VASCULATURE, 2024, 53
  • [40] Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
    Bin Feng
    Peiran Yu
    Hao Yu
    Buyun Qian
    Yuan Li
    Kangyun Sun
    Bimin Shi
    Nannan Zhang
    Guidong Xu
    Diabetology & Metabolic Syndrome, 15
12345